Loading news...
Kewaunee Scientific Corporation (NASDAQ: KEQU - Get Free Report) CEO Thomas David Hull III sold 884 shares of the business's stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $38.01, for a total transaction of $33,600.84. Following the sale, the chief executive officer owned 35,835 shares
KEQU posts sharp Q2 sales growth, driven by strong backlog and Nu Aire, but earnings decline amid project timing volatility and higher costs.
STATESVILLE, N.C. , Dec. 10, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its second quarter ended October 31, 2025.
STATESVILLE, N.C. , Dec. 4, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, today announced its successful debt refinancing and the full repayment of its Seller Notes.
STATESVILLE, N.C. , Nov. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading.
KEQU's Q1 revenues and EPS grow y/y, aided by Nu Aire, yet shares drop 19% as investors weigh uneven project timelines and rising costs.
STATESVILLE, N.C. , Sept. 10, 2025 /PRNewswire/ -- PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first quarter ended July 31, 2025.
STATESVILLE, N.C. , Sept. 2, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company will attend the 2025 Arablab Live tradeshow and conference, taking place in Dubai from September 23-25.
STATESVILLE, N.C. , Aug. 27, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its first quarter fiscal year 2026 financial results on Wednesday, September 10, 2025 after the close of trading.
KEQU earns an upgrade to "Outperform" as Nu Aire integration drives sales growth, margins expand and a record backlog boosts visibility, offsetting tariff risks with proactive inventory strategies.
KEQU posts strong Q4 and FY25 results, driving a 47% stock surge as sales jump and the Nu Aire acquisition boosts growth momentum.
Kewaunee Scientific's strong FY2025 results, record backlog, and margin expansion signal a return to growth and improved business predictability. Adjusted EPS actually rose 28% year-over-year, once non-recurring items and acquisition costs are excluded, reflecting core operational strength. A 38% increase in backlog suggests robust revenue growth for FY2026, supporting a bullish outlook and more potential stock upside.
STATESVILLE, N.C. , June 25, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2025.
STATESVILLE, N.C. , June 11, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release financial results for its fourth quarter and fiscal year ended April 30, 2025 on Wednesday, June 25, 2025 after the close of trading.
Kewaunee Scientific's revenues rise 43.6% in Q3, but profits decline due to higher expenses and Nu Aire acquisition costs. Backlog hits $221.6 million.
STATESVILLE, N.C. , March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced an amendment to its existing share repurchase program.
STATESVILLE, N.C. , March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its third quarter ended January 31, 2025.
STATESVILLE, N.C. , Feb. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its third quarter fiscal year 2025 financial results on Wednesday, March 12, 2025 after the close of trading.
Kewaunee Scientific manufactures laboratory furniture and equipment, a growing market driven by the need for advancements in healthcare. Since 2022, the company has focused on improving its margins through stop selling directly in some markets where the company had to focus on producing and selling. This has been reflected in the expansion of margins, but growth has been mid-single digit, and I think it can continue like this in the future.